Johnson & Johnson vs Moderna, Inc. — Stock Comparison
Johnson & Johnson (JNJ) and Moderna, Inc. (MRNA) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson clearly outscores Moderna, Inc. on Q·Score (7 vs 4.8 out of 10), led by Quality (9.3 vs 0.6) and Valuation (6.5 vs 3). Moderna, Inc. scores higher on Growth, reflecting stronger revenue and earnings momentum. Analyst consensus targets imply greater upside for JNJ (+5.0%) than for MRNA (-13.2%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-144% margin).
Analyst Consensus
Fundamentals
Frequently Asked Questions
JNJ vs MRNA: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7/10 versus Moderna, Inc. (MRNA) at 4.8/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: JNJ or MRNA?
Moderna, Inc. (MRNA) scores higher on Growth (8.3/10 vs 5.1/10). Johnson & Johnson reports revenue growth (9.9% YoY) while Moderna, Inc. reports (260.2% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is JNJ or MRNA more attractively valued?
Johnson & Johnson (JNJ) scores higher on Valuation (6.5/10 vs 3/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about JNJ vs MRNA?
There are 23 analysts covering JNJ with a consensus price target of $252.87, and 20 analysts covering MRNA with a consensus target of $43.30. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: JNJ or MRNA?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 0.6/10). Net profit margin: JNJ at 21.8%, MRNA at -143.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: JNJ or MRNA?
Moderna, Inc. (MRNA) scores higher on Financial Health (9.4/10 vs 6.5/10). Market beta: JNJ at 0.26, MRNA at 1.03. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of JNJ and MRNA?
Johnson & Johnson (JNJ) has a market capitalisation of $579.8B, while Moderna, Inc. (MRNA) has a market cap of $19.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do JNJ or MRNA pay dividends?
JNJ pays a dividend yield of 2.23%, while MRNA does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →